Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 513 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Corvus Pharmaceuticals, Inc.
Market Cap
$892.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$892.87M
Gross Margin
99.98%
TTM Avg
98.71%
3Y Avg
99.36%
5Y Avg
-14.89%
Market Cap
$917.68M
Gross Margin
65.08%
TTM Avg
65.58%
3Y Avg
65.74%
5Y Avg
65.17%
Market Cap
$851.97M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
Market Cap
$866.05M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$853.35M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $892.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| Arbutus Biopharma Corp (ABUS)vs › | $892.87M | 99.98% | 98.71% | 99.36% | -14.89% |
| Bioventus Inc. (BVS)vs › | $916.63M | 68.00% | 67.52% | 65.94% | 67.78% |
| HealthStream, Inc. (HSTM)vs › | $917.68M | 65.08% | 65.58% | 65.74% | 65.17% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $851.97M | 92.94% | 91.25% | 45.63% | 30.42% |
| Beta Bionics, Inc. (BBNX)vs › | $866.05M | 58.31% | 55.25% | 65.77% | 65.77% |
| Apnimed, Inc. (APMD)vs › | $864.96M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $853.35M | 0.00% | 0.00% | 0.00% | 0.00% |
| CeriBell, Inc. (CBLL)vs › | $949.71M | 88.90% | 87.31% | 85.47% | 85.47% |
| Kura Oncology, Inc. (KURA)vs › | $940.12M | 94.73% | 99.96% | 49.98% | 33.32% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
